BMJ1d
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine
Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands Professor R Landewé, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical ...
BMJ2d
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
Objectives High levels of vascular endothelial growth factor (VEGF), a key angiogenic factor, are present in patients with systemic sclerosis (SSc), but its role in the pathogenesis of fibrosis and ...
BMJ2d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ3d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
BMJ3d
AB0306 IMPACT OF TOFACITINIB ON LIPID METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-WORLD STUDY
Background Tofacitinib is the first Janus Kinase (JAK) inhibitor available in China, and it has significantly improved the efficacy of treatment of rheumatoid arthritis (RA). Previous clinical trials ...
BMJ3d
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
Objective: To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With recent therapeutic advances, this is now a goal for treatment and may represent a measure to compare ...
BMJ3d
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Objectives To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). Methods This study randomised patients (1:1) ...
BMJ3d
Long term high intensity exercise and damage of small joints in rheumatoid arthritis
1 Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands 2 Department of Physical and Occupational Therapy, LUMC, Leiden, The Netherlands 3 Department of Medical ...
BMJ4d
Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis
Correspondence to Dr Sylvain Mathieu, Rheumatology Department, Gabriel Montpied Teaching Hospital, 63003 Clermont-Ferrand, France; smathieu{at}chu-clermontferrand.fr We searched PubMed to find reports ...
BMJ4d
EULAR recommendations for patient education for people with inflammatory arthritis
19 Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands Correspondence to Dr Heidi A Zangi, National Advisory Unit on Rehabilitation in ...
BMJ6d
Patient preferences for psychological support in inflammatory arthritis: a multicentre survey
Objectives Inflammatory arthritis (IA) can lead to anxiety, depression, pain and fatigue. Psychological support can improve quality of life and self-management; and European and American guidelines ...